Updating results

576 results

Sort: Relevance | Date

Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 19 January 2022

NICE guideline In development

Advocacy services for adults with health and social care needs

In development [GID-NG10156] Expected publication date: 17 June 2022

NICE guideline In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 26 August 2020

Diagnostics guidance In development

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 26 August 2020

Diagnostics guidance In development

QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography

In development [GID-DG10034] Expected publication date: 30 September 2020

Diagnostics guidance In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

In development [GID-DG10023] Expected publication date: 27 May 2020

Diagnostics guidance In development

Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain

In development [GID-DG10036] Expected publication date: 12 May 2021

Diagnostics guidance In development

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Proposed [GID-TA10612] Expected publication date: TBC

Technology appraisal guidance Proposed

Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

Proposed [GID-TA10566] Expected publication date: TBC

Technology appraisal guidance Proposed

Eflornithine with sulindac for treating familial adenomatous polyposis ID1543

Proposed [GID-TA10536] Expected publication date: TBC

Technology appraisal guidance Proposed

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

Proposed [GID-TA10544] Expected publication date: TBC

Technology appraisal guidance Proposed

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

Proposed [GID-TA10520] Expected publication date: TBC

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 10 June 2020

Technology appraisal guidance Proposed

Semaglutide for treating type 2 diabetes (ID1450)

Proposed [GID-TA10438] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: 16 December 2020

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating severe eosinophilic asthma [ID3750]

Proposed [GID-TA10622] Expected publication date: TBC

Technology appraisal guidance Proposed

Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

Proposed [GID-TA10558] Expected publication date: TBC

Technology appraisal guidance Proposed

Ponesimod for treating relapsing multiple sclerosis [ID1393]

Proposed [GID-TA10556] Expected publication date: TBC

Technology appraisal guidance Proposed

Ofatumumab for treating relapsing multiple sclerosis [ID1677]

Proposed [GID-TA10557] Expected publication date: TBC

Technology appraisal guidance Proposed

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

Proposed [GID-TA10561] Expected publication date: TBC

Technology appraisal guidance Proposed

Baloxavir marboxil for treating influenza [ID1537]

Proposed [GID-TA10559] Expected publication date: TBC

Technology appraisal guidance Proposed

Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

Proposed [GID-TA10560] Expected publication date: TBC

Technology appraisal guidance Proposed

Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Technology appraisal guidance Proposed

Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Proposed [GID-TA10524] Expected publication date: 16 September 2020

Technology appraisal guidance Proposed

Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Proposed [GID-TA10603] Expected publication date: TBC

Technology appraisal guidance Proposed

Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Technology appraisal guidance Proposed

Fostemsavir for treating multidrug resistant HIV-1 [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Technology appraisal guidance Proposed

Avalglucosidase alfa for treating late-onset glycogen storage disease type II [ID3737]

Proposed [GID-TA10594] Expected publication date: TBC

Technology appraisal guidance Proposed

Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]

Proposed [GID-TA10595] Expected publication date: TBC

Technology appraisal guidance Proposed

Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

Proposed [GID-TA10596] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

Proposed [GID-TA10597] Expected publication date: TBC

Technology appraisal guidance Proposed

Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

Proposed [GID-TA10562] Expected publication date: TBC

Technology appraisal guidance Proposed

Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

Proposed [GID-TA10563] Expected publication date: TBC

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed